Observational studyJACC. Cardiovascular interventions2024
Long-Term Impact of Cardiac Damage Following Transcatheter Aortic Valve Replacement.
Observational study in JACC. Cardiovascular interventions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01368250 (SwissTAVI Registry), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SwissTAVI Registry: Prospective, National, Multi-Center Registry of Patients Undergoing Transcatheter Aortic Valve Implantation
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Trajectories of cardiac damage staging after transcatheter aortic valve replacement and long-term outcomes.Cardiovascular intervention and therapeutics · 2026Article
- Integrated Impact of Post-TAVR Cardiac Damage and Pacemaker Implantation on Long-Term Outcomes.Biomedicines · 2026Article
- Prognostic Impact of Residual Renal Congestion at Discharge After Transcatheter Aortic Valve Implantation.CJC open · 2026Article
- Aortic Stenosis-Associated Cardiac Damage: A Comparison Between Patients Treated with Surgery and Transcatheter Aortic Valve Replacement.Journal of clinical medicine · 2026Article
- Right-Sided Extravalvular Damage: An Overlooked Driver of Risk Model Failure in Low-Flow, Low-Gradient Aortic Stenosis.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Association between pre-procedural computed tomography angiography-based global longitudinal strain and outcomes in patients undergoing transcatheter aortic valve implantation.Quantitative imaging in medicine and surgery · 2025Article
- Loop Diuretic Therapy in Severe Aortic Stenosis: Marker of Organ Congestion, Unfavorable Hemodynamics, and Increased Post-Valve Replacement Mortality.Clinical cardiology · 2025Article
- Effect of Transcatheter Aortic Valve Implantation on Non-Invasive Myocardial Work Parameters: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Cardiac structural and functional damage induced and/or increasingly aggravated by aortic valve stenosis.Cardiovascular diagnosis and therapy · 2025Article
- Rapid Improvement in Cardiac Damage Predicts Better Prognosis After Transcatheter Aortic Valve Replacement.Journal of cardiovascular development and disease · 2025Article
- SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI).Cardiovascular diabetology · 2024Observational
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtravalvular cardiac damage caused by aortic stenosis affects prognosis after transcatheter aortic valve replacement (TAVR). The long-term impact of changes in cardiac damage in response to relief from mechanical obstruction has not been fully investigated.
objectivesThe authors aimed to investigate changes in cardiac damage early after TAVR and the prognostic impact of the cardiac damage classification after TAVR.
methodsIn this single-center observational study, patients undergoing transfemoral TAVR were retrospectively evaluated for cardiac damage before and after TAVR and classified into 5 stages of cardiac damage (0-4).
resultsAmong 1,863 patients undergoing TAVR between January 2007 and June 2022, 56 patients (3.0%) were classified as stage 0, 225 (12.1%) as stage 1, 729 (39.1%) as stage 2, 388 (20.8%) as stage 3, and 465 (25.0%) as stage 4. Cardiac stage changed in 47.7% of patients (improved: 30.1% in stages 1-4 and deteriorated: 24.7% in stages 0-3) early after TAVR. Five-year all-cause mortality was associated with cardiac damage both at baseline (HR
conclusionsThe extent of extra-aortic valve cardiac damage before and after TAVR and changes in cardiac stage early after TAVR have important prognostic implications during long-term follow-up. (SwissTAVI Registry; NCT01368250).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.